Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Memorial Sloan Kettering Cancer Center · Sun Yat-sen University · +28 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
235
total citations
- FWCI
- 69.75
- Percentile
- 100%
- References
- 40
Citations per year
Authors
63- JJJames J. HardingCorresponding
Memorial Sloan Kettering Cancer Center
- JFJia Fan
Sun Yat-sen University, Fudan University, Zhongshan Hospital, The First Affiliated Hospital, Sun Yat-sen University
- DODo‐Youn Oh
Seoul National University Hospital
- HJHye Jin Choi
Yonsei University
- JWJin Won Kim
Seoul National University Bundang Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Internal medicine
- Cohort
- Tolerability
- Biliary tract cancer
- Clinical endpoint
- Oncology
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.